On Monday, Allogene Therapeutics Inc (NASDAQ: ALLO) opened lower -5.81% from the last session, before settling in for the closing price of $1.55. Price fluctuations for ALLO have ranged from $1.32 to $4.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -43.16% over the past five years. Company’s average yearly earnings per share was noted 9.90% at the time writing. With a float of $139.53 million, this company’s outstanding shares have now reached $212.21 million.
Let’s look at the performance matrix of the company that is accounted for 229 employees. In terms of profitability, gross margin is -32622.73%, operating margin of -1219136.36%, and the pretax margin is -1168850.0%.
Allogene Therapeutics Inc (ALLO) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Allogene Therapeutics Inc is 35.78%, while institutional ownership is 63.64%. The most recent insider transaction that took place on Mar 14 ’25, was worth 91,469. In this transaction President and CEO of this company sold 46,668 shares at a rate of $1.96, taking the stock ownership to the 5,276,569 shares. Before that another transaction happened on Mar 14 ’25, when Company’s SVP, Chief Technical Officer sold 5,488 for $1.98, making the entire transaction worth $10,839. This insider now owns 218,507 shares in total.
Allogene Therapeutics Inc (ALLO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 9.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.15% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Check out the current performance indicators for Allogene Therapeutics Inc (ALLO). In the past quarter, the stock posted a quick ratio of 8.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15860.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 2.43 million, a negative change from its year-to-date volume of 5.5 million. As of the previous 9 days, the stock’s Stochastic %D was 17.29%. Additionally, its Average True Range was 0.19.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 5.69%, which indicates a significant decrease from 9.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.20% in the past 14 days, which was lower than the 111.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8450, while its 200-day Moving Average is $2.3532. Nevertheless, the first resistance level for the watch stands at $1.5113 in the near term. At $1.5625, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6232. If the price goes on to break the first support level at $1.3994, it is likely to go to the next support level at $1.3387. Assuming the price breaks the second support level, the third support level stands at $1.2875.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
There are currently 217,265K shares outstanding in the company with a market cap of 317.21 million. Presently, the company’s annual sales total 20 K according to its annual income of -257,590 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -59,940 K.
